Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia

Journal of Hematology & Oncology

Yangqiu Li²  Shaohua Chen¹  Lijiang Yang¹  Jing Lai¹  Xibao Yu²  Chengwu Zeng² 

[1] Institute of Hematology, Medical College, Jinan University, Guangzhou 510632, China;Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou 510632, China

关键词: Differentiation;    All-trans retinoic acid;    Acute promyelocytic leukemia;    Long non-coding RNA;   

Others  :  1233264
DOI  :  10.1186/s13045-015-0223-4

 received in 2015-10-14, accepted in 2015-11-03,  发布年份 2015

【 摘 要 】

Background

Acute promyelocytic leukemia (APL) is associated with chromosomal translocation t(15;17), which results in the proliferation of morphologically abnormal promyelocytes. Gain of supernumerary copies of the 8q24 chromosomal region, which harbors MYC and PVT1, has been shown to be the most common secondary alteration in human APL. Increased MYC can accelerate the development of myeloid leukemia in APL. However, the role that the expression of the long non-coding RNA (lncRNA) PVT1 plays in the pathogenesis of APL remains largely unknown.

Findings

In this study, we first analyzed the lncRNA PVT1 expression level in peripheral blood cells from 28 patients with de novo APL, and significantly upregulated PVT1 was found in APL patients compared with healthy donors. We then observed significantly lower MYC and PVT1 expression during all-trans retinoic acid (ATRA)-induced differentiation and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1 knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited.

Conclusion

Our findings reveal that the lncRNA PVT1 may play an important role in the proliferation of APL cells and may be useful for future therapeutic management.

【 授权许可】

   
2015 Zeng et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M et al.. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993; 74(3):423-431.
• [2]Duprez E, Wagner K, Koch H, Tenen DG. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 2003; 22(21):5806-5816.
• [3]Wang K, Wang P, Shi J, Zhu X, He M, Jia X et al.. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010; 17(2):186-197.
• [4]Zeng CW, Chen ZH, Zhang XJ, Han BW, Lin KY, Li XJ et al.. MIR125B1 represses the degradation of the PML-RARA oncoprotein by an autophagy-lysosomal pathway in acute promyelocytic leukemia. Autophagy. 2014; 10(10):1726-1737.
• [5]Qian M, Jin W, Zhu X, Jia X, Yang X, Du Y et al.. Structurally differentiated cis-elements that interact with PU.1 are functionally distinguishable in acute promyelocytic leukemia. J Hematol Oncol. 2013; 6:25. BioMed Central Full Text
• [6]Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N et al.. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood. 2006; 107(8):3330-3338.
• [7]Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011; 117(22):5795-5802.
• [8]Loewen G, Jayawickramarajah J, Zhuo Y, Shan B. Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol. 2014; 7(1):90. BioMed Central Full Text
• [9]Dzikiewicz-Krawczyk A. MicroRNA-binding site polymorphisms in hematological malignancies. J Hematol Oncol. 2014; 7(1):83. BioMed Central Full Text
• [10]Wang WT, Chen YQ. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014; 7(1):86. BioMed Central Full Text
• [11]Zeng CW, Zhang XJ, Lin KY, Ye H, Feng SY, Zhang H et al.. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. Mol Pharmacol. 2012; 81(4):578-586.
• [12]Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT et al.. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007; 316(5830):1484-1488.
• [13]Zeng C, Xu Y, Xu L, Yu X, Cheng J, Yang L et al.. Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer. 2014; 14:693. BioMed Central Full Text
• [14]Morlando M, Ballarino M, Fatica A. Long non-coding RNAs: new players in hematopoiesis and leukemia. Front Med. 2015; 2:23.
• [15]Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L et al.. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. J Hematol Oncol. 2014; 7:63. BioMed Central Full Text
• [16]Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.
• [17]Zhuang Y, Wang X, Nguyen HT, Zhuo Y, Cui X, Fewell C et al.. Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen. J Hematol Oncol. 2013; 6:35. BioMed Central Full Text
• [18]Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS et al.. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014; 111(52):18679-18684.
• [19]Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L et al.. High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett. 2014; 588(9):1780-1786.
• [20]Imamura K, Imamachi N, Akizuki G, Kumakura M, Kawaguchi A, Nagata K et al.. Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune stimuli. Mol Cell. 2014; 53(3):393-406.
• [21]Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I et al.. Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Lett. 2014; 352(1):90-96.
• [22]Zhang X, Weissman SM, Newburger PE. Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells. RNA Biol. 2014; 11(6):777-787.
• [23]Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C et al.. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14(12):1333-1342.
• [24]Lallemand-Breitenbach V, Zhu J, Chen Z, de The H. Curing APL through PML/RARA degradation by As2O3. Trends Mol Med. 2012; 18(1):36-42.
• [25]Kogan SC. Curing APL: differentiation or destruction? Cancer Cell. 2009; 15(1):7-8.
• [26]Ward SV, Sternsdorf T, Woods NB. Targeting expression of the leukemogenic PML-RARalpha fusion protein by lentiviral vector-mediated small interfering RNA results in leukemic cell differentiation and apoptosis. Hum Gene Ther. 2011; 22(12):1593-1598.
• [27]Walter MJ, Park JS, Lau SK, Li X, Lane AA, Nagarajan R et al.. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol. 2004; 24(24):10882-10893.
• [28]Le Beau MM, Bitts S, Davis EM, Kogan SC. Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood. 2002; 99(8):2985-2991.
• [29]Shtivelman E, Bishop JM. Effects of translocations on transcription from PVT. Mol Cell Biol. 1990; 10(4):1835-1839.
• [30]Chinen Y, Sakamoto N, Nagoshi H, Taki T, Maegawa S, Tatekawa S et al.. 8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia. J Hematol Oncol. 2014; 7:68. BioMed Central Full Text
• [31]Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A et al.. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med. 2010; 207(12):2581-2594.
• [32]Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, Giallongo A et al.. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007; 213(2):511-518.
• [33]Theilgaard-Monch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC et al.. The transcriptional program of terminal granulocytic differentiation. Blood. 2005; 105(4):1785-1796.
• [34]Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C et al.. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014; 60(4):1278-1290.
• [35]Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS, Feng XJ. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. I J Clin Exp Pathol. 2014; 7(10):6929-6935.
• [36]Huang C, Yu W, Wang Q, Cui H, Wang Y, Zhang L et al.. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med. 2015; 106(3):143-149.
• [37]Ding J, Li D, Gong M, Wang J, Huang X, Wu T et al.. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. OncoTargets Ther. 2014; 7:1625-1630.
• [38]Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE et al.. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res. 2008; 6(2):212-221.
• [39]Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002; 99(6):2199-2206.
• [40]Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H et al.. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014; 512(7512):82-86.
• [41]Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7(1):70. BioMed Central Full Text
• [42]Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC et al.. Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol. 2013; 2(1):10. BioMed Central Full Text
• [43]Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C et al.. Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014; 3:17. BioMed Central Full Text
• [44]Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003; 6(4):283-287.
• [45]Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RD, McArthur GA. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood. 2008; 112(6):2305-2317.
• [46]Huang HL, Weng HY, Wang LQ, Yu CH, Huang QJ, Zhao PP et al.. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012; 11(5):1155-1165.
• [47]Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H et al.. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014; 110(1):164-171.
• [48]Miyake M, Hayashi S, Iwasaki S, Chao G, Takahashi H, Watanabe K et al.. Possible role of TIEG1 as a feedback regulator of myostatin and TGF-beta in myoblasts. Biochem Biophys Res Commun. 2010; 393(4):762-766.